Main Business / Finance News Today
Piedmont Lithium receives extension as it pursues North Carolina permit for...
$47 million apartment project near UC gets Port aid
Bronzeville Center for the Arts unveils project team with minority-owned...
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Dividend...
Bank of America employees to share in restricted stock award
KAINANTU RESOURCES CLOSES C$2.5M OVERSUBSCRIBED FINAL TRANCHE FINANCING TO...
2023-01-25 07:00:00

Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings

Logo Benzinga
Benzinga
By Business Wire

Regulatory News:

Lysogene (FR0013233475 LYS) LYS, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard proceedings which has been in place since December 13, 2022 into reorganization proceedings.

As announced on January 6, 2023, in the absence of a solution to strengthen its financial situation and secure its cash runway during the safeguard proceedings, Lysogene together with the judicial administrator, filed a request with the Commercial Court of Nanterre for the conversion of the safeguard proceedings into reorganization proceedings. This request was examined and approved by the Commercial Court of Nanterre at the hearing of January 24, 2023.

In this context, Lysogene reminds that a bidding process for the purpose of finding buyers or investors has been published by the judicial administrator on January 6, 2023 and that the deadline for the submission of offers has been set by the latter to February 15, 2023 at 12:00 am.

Continue read on benzinga.com

Related Posts
Logo GlobeNewswire
SciencePress Release2023-01-24 21:01:00
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers...
Logo PR Newswire
Business / FinancePress Release2023-01-24 14:00:00
Lysander Announces Cash Distributions for the Lysander ActivETFs
TORONTO, Jan. 24, 2023 /CNW/ - Lysander Funds Limited ("Lysander") announces the January, February, and March 2023 cash distributions for each of...
Logo GlobeNewswire
SciencePress Release2023-01-24 16:45:00
Conversion of the receivership proceedings into judicial liquidation proceedings
CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 23:46:00
EQUITY ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Bioventus Inc. Investors with Losse
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of Bioventus Inc....
Logo Benzinga
Business / FinanceBy Business Wire2023-01-06 16:21:00
Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceed
Regulatory News: Lysogene (FR0013233475 LYS) LYS, a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it...
Logo GlobeNewswire
SciencePress Release2023-01-24 21:15:00
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma...
Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:36:00
FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC System for the Treatment of Ischem
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix, Inc., a privately...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 03:13:00
Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Remind
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 14:01:00
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Act
Robbins Geller Rudman & Dowd LLP announces that purchasers of Y-mAbs Therapeutics, Inc. YMAB common stock on the open market, or pursuant to Registration...
Logo PR Newswire
HealthPress Release2023-01-25 00:18:00
CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, Jan. 24, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 06:00:00
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Eng
Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Cerevance to Participate at the SVB Global Biopharma Conference
BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS)...
Logo PR Newswire
TechnologyPress Release2023-01-24 14:00:00
Aetion Collaborates With FDA to Explore Oncology RWD for Regulatory Science Research
Aetion and FDA will use the Aetion Evidence Platform ® to study crucial oncology research questions to advance the mission of the Oncology Center of...
Logo PR Newswire
HealthPress Release2023-01-24 13:00:00
Geneoscopy Submits Premarket Approval Application to U.S. Food and Drug Administration for its Noninvasive Colorectal...
FDA's Decision Forthcoming for Innovative Test with Agency's Breakthrough Device Designation ST. LOUIS, Jan. 24, 2023 /PRNewswire/ -- Geneoscopy Inc., a life...
Logo PR Newswire
HealthPress Release2023-01-24 12:36:00
FDA Agrees to Expanded Access Program for the BioVentrix® Revivent TC® System for the Treatment of Ischemic Heart...
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix ®, Inc., a...
Logo PR Newswire
Business / FinancePress Release2023-01-24 10:45:00
YMAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 20, 2023 in the Class Action Filed on...
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Y-mAbs...
Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:45:00
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
Phase 1/2 clinical trial expected to launch in early 2023 and will evaluate safety and preliminary impact on disease activity of IMPT-314 WEST HILLS, Calif.,...
Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of...
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its...
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today...
Logo GlobeNewswire
SciencePress Release2023-01-24 21:25:00
Jasper Therapeutics Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing...